Regulation (EU) 2024/1381
Commission Implementing Regulation (EU) 2024/1381 of 23 May 2024 laying down, pursuant to Regulation (EU) 2021/2282 on health technology assessment, procedural rules for the interaction during, exchange of information on, and participation in, the preparation and update of joint clinical assessments of medicinal products for human use at Union level, as well as templates for those joint clinical assessments
In forceTyperegulationDate23 May 2024Since25 Sep 2024Articles22Versions held50Cited by2 documents
- 1Subject matter
- 2Relevant information for the development of the assessment scope
- 3Exchange of information with the European Medicines Agency
- 4Information to the Coordination Group
- 5Information to the health technology developer about the start of a joint clinical assessment
- 6Selection of patients, clinical experts and other relevant experts
- 7Professional secrecy obligations of patients, clinical experts and other relevant experts
- 8Consultation of stakeholder organisations during joint clinical assessments
- 9Assessment scope proposal
- 10Finalisation of the assessment scope
- 11Assessment scope explanation meeting
- 12Dossier and further data for joint clinical assessment provided by the health technology developer
- 13Commission’s confirmation of the dossier for a joint clinical assessment
- 14Draft joint clinical assessment and summary reports
- 15Finalisation of the revised draft joint clinical assessment and summary reports
- 16Changes to the therapeutic indication(s)
- 17Re-initiation of joint clinical assessments
- 18Updates of joint clinical assessments
- 19Correspondence during joint clinical assessments
- 20Confidentiality requests
- 21Personal data processing
- 22Entry into force and date of application
- ANNEX I
- 2 Appendixes
- ANNEX II
- 4 Appendixes
- ANNEX III
Source: EU legislation in force, consolidated versions and treaties (Cellar, Publications Office). Official publication. Reuse: Reuse authorised (Commission Decision 2011/833/EU).